Irene Y Cheung

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Mol Diagn 9:237-41. 2007
  2. doi request reprint Early negative minimal residual disease in bone marrow after immunotherapy is less predictive of late or non-marrow relapse among patients with high-risk stage 4 neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 60:E32-4. 2013
  3. pmc Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor
    Irene Y Cheung
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 30:426-32. 2012
  4. ncbi request reprint Prognostic significance of GAGE detection in bone marrows on survival of patients with metastatic neuroblastoma
    I Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 35:632-4. 2000
  5. pmc Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma
    Irene Y Cheung
    Department of Pediatrics and Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 14:7020-7. 2008
  6. ncbi request reprint Novel markers of subclinical disease for Ewing family tumors from gene expression profiling
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:6978-83. 2007
  7. ncbi request reprint Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 119:152-6. 2006
  8. ncbi request reprint Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR
    I Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center New York, New York 10021, USA
    Clin Cancer Res 7:1698-705. 2001
  9. ncbi request reprint Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:3853-8. 2003
  10. ncbi request reprint Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:1087-93. 2003

Research Grants

  1. Molecular Detection of Occult Neuroblastoma
    Irene Cheung; Fiscal Year: 2004

Detail Information

Publications27

  1. pmc Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Mol Diagn 9:237-41. 2007
    ..We conclude that CCND1 has potential clinical utility as a novel molecular marker of MRD in the bone marrow of patients with metastatic NB...
  2. doi request reprint Early negative minimal residual disease in bone marrow after immunotherapy is less predictive of late or non-marrow relapse among patients with high-risk stage 4 neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 60:E32-4. 2013
    ..We conclude that negative MRD in the post-cycle two BM was rarely associated with BM relapse, but it did not exclude recurrences at other sites...
  3. pmc Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor
    Irene Y Cheung
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 30:426-32. 2012
    ..Although there is ample evidence on how the antibody targets NB, in vivo contribution by GM-CSF remains unclear. This report investigates granulocyte activation and its correlation with treatment outcome...
  4. ncbi request reprint Prognostic significance of GAGE detection in bone marrows on survival of patients with metastatic neuroblastoma
    I Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 35:632-4. 2000
    ..Among patients with stage III melanoma rendered disease-free by surgery, GAGE expression was a strong prognostic factor for patient survival...
  5. pmc Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma
    Irene Y Cheung
    Department of Pediatrics and Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 14:7020-7. 2008
    ..Because of tumor heterogeneity, no single marker will likely be adequate. Genome-wide expression profiling can uncover potential MRD markers differentially expressed in tumors over normal marrow/blood...
  6. ncbi request reprint Novel markers of subclinical disease for Ewing family tumors from gene expression profiling
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:6978-83. 2007
    ..Genome-wide expression arrays can uncover novel genes differentially expressed in tumors over normal marrow/blood, which may have potentials as markers of subclinical disease...
  7. ncbi request reprint Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 119:152-6. 2006
    ..Similarly, the STX transcript level of posttreatment marrows was also highly prognostic of outcome (PFS, p = 0.001; OS, p < 0.0005). We conclude that STX mRNA has potential clinical utility as a molecular marker of metastatic NB...
  8. ncbi request reprint Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR
    I Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center New York, New York 10021, USA
    Clin Cancer Res 7:1698-705. 2001
    ..We explore the potential of GD2 synthase mRNA as a molecular marker of minimal residual disease by first comparing it quantitatively with immunocytology and then testing its clinical utility...
  9. ncbi request reprint Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:3853-8. 2003
    ..To use early marrow response as a prognostic marker is particularly relevant for patients not likely to benefit from this therapy...
  10. ncbi request reprint Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:1087-93. 2003
    ..Because therapy (myeloablation, immunotherapy, or differentiation) for MRD is applied at the time of clinical remission, objective surrogate markers are needed to gauge treatment efficacy...
  11. ncbi request reprint Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 94:3042-8. 2002
    ..Its utility in bone marrow (BM) purging is evaluated by a real-time reverse transcription-polymerase chain reaction (RT-PCR) assay to quantify the mRNA of GD2 synthase, the key enzyme in GD2 synthesis...
  12. ncbi request reprint FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:2885-90. 2006
    ..Granulocyte macrophage colony-stimulating factor (GM-CSF) enhances phagocyte-mediated ADCC. The differential affinity of the human FCGR polymorphic alleles for 3F8 may influence the effectiveness of antibody immunotherapy...
  13. ncbi request reprint High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Pediatr Blood Cancer 48:430-4. 2007
    ..We assessed the impact on rapid HAMA formation of prior chemotherapy in NB patients...
  14. pmc Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 30:3264-70. 2012
    ..Anti-GD2 monoclonal antibody (MoAb) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) has shown efficacy against neuroblastoma (NB). Prognostic variables that could influence clinical outcome were explored...
  15. ncbi request reprint Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer 101:2303-8. 2004
    ..Circulating tumor cells in peripheral blood (PB) derive from depots other than BM, and its measurement may provide additional information in the management of patients with NB...
  16. pmc KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma
    Jeffrey M Venstrom
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 15:7330-4. 2009
    ..We hypothesized that patients with a "missing ligand" KIR-HLA compound genotype may uniquely benefit from autologous hematopoietic stem cell transplantation (HSCT)...
  17. pmc MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors
    Hong Xu
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 69:6275-81. 2009
    ..Differential modulation of this key immunoinhibitory molecule in tumor versus normal tissues may advance both cell-mediated immunotherapy and antibody-based targeted strategies using the B7-H3-specific mAb 8H9...
  18. doi request reprint Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer
    Lin Chi Chen
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, 1275 York Ave, New York, NY, United States
    Lung Cancer 67:216-20. 2010
    ..We conducted this study to determine if GD2/GM2 synthase RNA could be detected in SCLC cell lines and human tissues, and whether mRNA transcript levels corresponded with disease status...
  19. pmc Association of age at diagnosis and genetic mutations in patients with neuroblastoma
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    JAMA 307:1062-71. 2012
    ..Neuroblastoma is diagnosed over a wide age range from birth through young adulthood, and older age at diagnosis is associated with a decline in survivability...
  20. doi request reprint Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Pediatr Blood Cancer 58:469-71. 2012
    ..Hematopoietic reconstitution was achieved in all three patients receiving plerixafor-primed stem cells after myeloablative therapy. Plerixafor is an effective and safe agent for stem cell collection in patients with NB...
  21. ncbi request reprint Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission
    Brian H Kushner
    Authors Affiliations Departments of Pediatrics and Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Cancer Res 20:1375-82. 2014
    ..gov NCT00911560). Secondary objectives were to obtain preliminary data on immune response and activity against minimal residual disease (MRD). Treatment also included the immunostimulant β-glucan...
  22. doi request reprint Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases
    David Cobrinik
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065
    Genes Chromosomes Cancer 52:1150-66. 2013
    ..Among the acquired lesions, increased TERT copy number and expression appears likely to function in lieu of MYCNA to promote CNS metastasis...
  23. ncbi request reprint Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma
    Hong Xu
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Cancer 129:1953-62. 2011
    ..These results suggest a therapeutic potential of combination therapy using checkpoint kinase inhibitor and chemotherapy to reverse or prevent drug resistance in treating neuroblastomas with defective G(1) checkpoints...
  24. pmc MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas
    Ruimin Huang
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    FASEB J 25:4138-49. 2011
    ....
  25. ncbi request reprint Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hybrid Hybridomics 22:209-18. 2003
    ..Anti-idiotypic antibody may provide a useful tool for optimizing gene transduction of CIR fusion constructs into primary human lymphocytes and their continual expansion in vitro...
  26. ncbi request reprint Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteins
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hybrid Hybridomics 21:433-43. 2002
    ..The reduced size resulted in a shorter half-life in vivo, while achieving comparable tumor to nontumor ratio as the native antibody 8H9. However, its in vitro activity in antibody-dependent cell-mediated cytotoxicity was modest...
  27. ncbi request reprint Detecting minimal residual disease in neuroblastoma patients-the present state of the art
    Klaus Beiske
    Department of Pathology, Rikshospitalet, Sognsvannsveien 23, N 0027 Oslo, Norway
    Cancer Lett 228:229-40. 2005
    ....

Research Grants1

  1. Molecular Detection of Occult Neuroblastoma
    Irene Cheung; Fiscal Year: 2004
    ..If these two molecular markers of MRD can independently predict patient outcome, they will in the future provide an objective endpoint for stopping further treatment, and serve as sensitive surrogates for evaluating adjuvant therapies. ..